Erlinda Gordon, MD, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, explains the rationale of using the combination therapy of ipilimumab plus nivolumab plus trabectedin in the first-line for patients with advanced leiomyosarcoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
